{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:13:18Z","timestamp":1778818398524,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022790","name":"Hector Stiftung II","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010564","name":"Deutsches Zentrum f\u00fcr Lungenforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cllc.2026.03.005","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:29:00Z","timestamp":1773854940000},"page":"97-107.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8541-7206","authenticated-orcid":false,"given":"Cornelia","family":"Kropf-Sanchen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaj","family":"Frost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Kuon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Wermke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Wiesweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine T.","family":"Gaisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Josten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carina","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Buth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Glanemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias F.","family":"Froelich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Janning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Colienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Haselmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Loges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2026.03.005_bib0001","series-title":"World Cancer Report: Cancer Research for Cancer Prevention","author":"Wild","year":"2020"},{"key":"10.1016\/j.cllc.2026.03.005_bib0002","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5858\/arpa.2016-0579-CP","article-title":"Worldwide frequency of commonly detected EGFR mutations","volume":"142","author":"Graham","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0003","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1056\/NEJMra1703413","article-title":"Precision diagnosis and treatment for advanced non\u2013small-cell lung cancer","volume":"377","author":"Reck","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0004","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR -mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0005","doi-asserted-by":"crossref","unstructured":"Planchard, D. First-line Osimertinib + chemotherapy versus osimertinib monotherapy in EGFRm advanced NSCLC: FLAURA2 final overall survival. in (Barcelona, 2025).","DOI":"10.1016\/j.jtho.2025.09.015"},{"key":"10.1016\/j.cllc.2026.03.005_bib0006","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","article-title":"Amivantamab plus Lazertinib in previously untreated EGFR -mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.cllc.2026.03.005_bib0007","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","article-title":"Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC","volume":"393","author":"Yang","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2026.03.005_bib0008","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cllc.2026.03.005_bib0009","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/curroncol32040191","article-title":"Resistance mutation profiles associated with current treatments for epidermal growth factor receptor-mutated non-small-cell lung cancer in the United States: a systematic literature review","volume":"32","author":"Vadagam","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0010","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2026.03.005_bib0011","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/cancers17040563","article-title":"Possibilities of overcoming resistance to osimertinib in NSCLC patients with mutations in the EGFR gene","volume":"17","author":"Nico\u015b","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.cllc.2026.03.005_bib0012","article-title":"Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-mutant lung cancers","volume":"2","author":"Offin","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0013","article-title":"Oncogenic fusions may be frequently present at resistance of EGFR tyrosine kinase inhibitors in patients with NSCLC: a brief report","volume":"1","author":"Enrico","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.cllc.2026.03.005_bib0014","first-page":"1","article-title":"RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer","volume":"20","author":"Wang","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0016","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lungcan.2013.07.009","article-title":"Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma","volume":"82","author":"Go","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2026.03.005_bib0017","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.cllc.2026.03.005_bib0018","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion\u2013positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0019","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion\u2013positive non\u2013small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0020","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET fusion\u2013Positive non\u2013Small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0021","first-page":"OF1","article-title":"Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers","author":"Rotow","year":"2023","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.cllc.2026.03.005_bib0022","article-title":"Durable response to combined osimertinib and pralsetinib treatment for osimertinib resistance due to novel intergenic ANK3-RET fusion in EGFR-mutated non\u2013small-cell lung cancer","volume":"6","author":"Urbanska","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0023","article-title":"Response to pralsetinib observed in meningeal-metastatic EGFR-mutant NSCLC with acquired RET fusion: a brief report","volume":"3","author":"Zhao","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.cllc.2026.03.005_bib0024","first-page":"1","article-title":"An acquired CCDC6:: RET gene fusion as resistance mechanism for osimertinib in exon 21 EGFR(L858R) -mutated non-small cell lung cancer and its successful management with osimertinib and selpercatinib: a case report and review of literature","author":"Lormans","year":"2025","journal-title":"J. Chemother."},{"key":"10.1016\/j.cllc.2026.03.005_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1580322","article-title":"Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature","volume":"15","author":"Resuli","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0026","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0027","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-025-13786-w","article-title":"Efficacy of liquid biopsy for genetic mutations determination in non-small cell lung cancer: a systematic review on literatures","volume":"25","author":"Jahani","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2026.03.005_bib0028","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00292-019-0605-4","article-title":"The national Network Genomic Medicine (nNGM) Model for innovative diagnostics and therapy of lung cancer within a public healthcare system","volume":"40","author":"B\u00fcttner","year":"2019","journal-title":"Pathol"},{"key":"10.1016\/j.cllc.2026.03.005_bib0029","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.5740\/jaoacint.18-0320","article-title":"Guidelines for validation of qualitative real-time PCR methods for molecular diagnostic identification of probiotics","volume":"102","author":"Shehata","year":"2019","journal-title":"J. AOAC Int."},{"key":"10.1016\/j.cllc.2026.03.005_bib0032","doi-asserted-by":"crossref","first-page":"26","DOI":"10.21037\/pcm-22-7","article-title":"Review: biological implications of oncogenic rearrangements in non-small cell lung cancer","volume":"5","author":"Di Marco","year":"2022","journal-title":"Precis. Cancer Med"},{"key":"10.1016\/j.cllc.2026.03.005_bib0033","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0034","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0035","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cllc.2026.03.005_bib0036","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cllc.2026.03.005_bib0037","article-title":"Diagnostic accuracy of droplet digital PCR and amplification refractory mutation system PCR for detecting EGFR mutation in cell-free DNA of lung cancer: a meta-analysis","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol"},{"key":"10.1016\/j.cllc.2026.03.005_bib0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730426000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T03:51:12Z","timestamp":1778817072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730426000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1525730426000392"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.005","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2026.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}